Compared to Estimates, Conmed (CNMD) Q4 Earnings: A Look at Key Metrics

Core Insights - Conmed (CNMD) reported revenue of $373.2 million for the quarter ended December 2025, marking a year-over-year increase of 7.9% and an EPS of $1.43 compared to $1.34 a year ago, exceeding the Zacks Consensus Estimate of $366.22 million by 1.91% [1] Financial Performance - The company delivered an EPS surprise of 8.61%, with the consensus EPS estimate being $1.32 [1] - Conmed's shares have returned -3.8% over the past month, while the Zacks S&P 500 composite increased by 0.8%, indicating potential underperformance in the near term with a Zacks Rank of 5 (Strong Sell) [3] Revenue Breakdown - Domestic revenue was $206.2 million, slightly above the average estimate of $205.31 million, reflecting a year-over-year change of 1.4% [4] - International revenue reached $167 million, surpassing the average estimate of $160.92 million, with a year-over-year increase of 17.1% [4] - Net sales in Orthopedic Surgery were $157.4 million, exceeding the estimated $147.41 million, representing a 13.2% year-over-year change [4] - Net sales for Capital Products were $52.6 million, slightly below the estimated $53.13 million, with an 8.2% year-over-year increase [4] - Net sales of Single-use Products totaled $320.6 million, above the average estimate of $313.1 million, reflecting a 7.8% year-over-year change [4] - Net sales in General Surgery were $215.8 million, below the estimated $218.82 million, with a year-over-year increase of 4.3% [4]